2020 Updates in Breast Cancer from San Antonio

The Updates from San Antonio meeting will provide clinicians state-of-the-art information on breast cancer research with focuses in the study on experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. The meeting aims to showcase a balance of clinical, translational, and basic research, while providing a forum for concise updates and in-depth discussion and analysis on the latest scientific findings and practice changing advances in breast cancer treatment from the 2019 San Antonio Breast Cancer Symposium.

Get Started Now

Enroll in Course

Learning Objectives

Identify novel targeted and immunologic approaches to therapy for various cancers

Assess emerging targeted and immunologic therapies

Integrate recent findings on healthcare disparities into optimal therapy selection for individual patients with cancer

Identify optimal therapies for patients and managing and mitigating side effects

Describe the role of nurses and other clinicians in counseling patients with cancer and integrating treatment recommendations to optimize care

Describe findings from recent clinical trials evaluating immunotherapies

Describe the role of nurses and other clinicians in counseling patients with cancer and integrating treatment recommendations to optimize care

Identify strategies to prevent and manage the treatment-related adverse events of targeted therapies and immunotherapies to improve tolerability and maintain quality of life

Accreditation Information

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 6.25 AMA PRA Category 1 CreditsTM for physicians and 6.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.  

How This Course Works

This course consists of pre-recorded sessions that took place at the 2020 Updates in Breast Cancer from San Antonio Review on January 25, 2020.

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

A link to the evaluation will be provided at the conclusion of the course.

If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.

Frequently Asked Questions

How do I access my CME/CE Credits?

A link will be provided you to you at the conclusion of the course. You will be asked to fill out a brief evaluation and your certificate will be automatically emailed back to you.

How long do I have access to the course?

The course will be available to access until April 16, 2023. 

Can I have face to face interaction with Instructor?

No, this is an online self-paced course with video demonstration. However, you are free to connect with the medical experts for each session on social media or contact the team and we will connect you.

How many credits can I obtain?

Amedco LLC designates this enduring activity for a maximum of 6.25 AMA PRA Category 1 CreditsTM for physicians and 6.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.  

Course Curriculum

  • 2020 Updates in Breast Cancer from San Antonio Learners Notification
    5 minutes
  • SABCS 2019 Highlights: An Overview of New Therapeutic Approaches for TNBC and BRCA Related Breast Cancer
    28 minutes
  • SABCS 2019 Highlights: Tucatinib + Trastuzumab + Capecitabine May Become the New SoC in HER2+ Metastatic Breast Cancer
    15 minutes
  • SABCS 2019 Highlights: New Data Demonstrate the Potential of Trastuzumab Deruxtecan Becoming the New SoC in HER2+ Metastatic Breast Cancer
    15 minutes
  • SABCS 2019 Highlights: T-DM1 May Be an Alternative to TH for Selected Patients With Stage I HER2+ Breast Cancer
    9 minutes
  • SABCS 2019 Highlights on ER+ Breast Cancer: Improvements in Long-Term Outcome After 5 yrs of Endocrine Therapy
    6 minutes
  • SABCS 2019 Highlights on Neoadjuvant Ribociclib + Letrozole vs. Chemo in HR+ Early Breast Cancer: More Studies Needed Before Replacing Chemo With CDK4/6
    6 minutes
  • SABCS 2019 Highlights on ER+ mBC: Palbociclib + ET Is Better Tolerated Than Capecitabine, but not More Effective + Menopausal Estrogen Replacement Reduced BC Risk and Mortality
    10 minutes
  • SABCS 2019 Highlights on Surgery in Breast Cancer: Core Biopsies and Imaging After Neoadjuvant Chemo Are Still Insufficient, Surgery Is Still Required
    25 minutes
  • SABCS 2019 Update on Radiation Therapy in Early BC: 10-yr Cumulative IBTR Incidence w/ External APBI Using IMRT Is Not Significantly Different Than w/ CF-WBI
    8 minutes
  • SABCS 2019 Highlights on Radiation Therapy in mBC: Is Radiation Therapy the Principal Curative Treatment w/ IO or Employed to Activate IO?
    9 minutes
  • SABCS 2019 Highlights: Overview of Clinical Trials on Survivorship and Quality of Life in Breast Cancer
    20 minutes
  • SABCS 2019 Highlights on Predictive Models and Biomarkers in BC: CTS5 Can Be Considered for Long-Term Risk Prognostication
    18 minutes
  • SABCS 2019 Highlights on Predictive Models and Biomarkers in BC: ctDNA’s Are not Ready for Prime Time, but Are Showing Immediate Relevance and Long-Term Promise
    20 minutes

Get Started Now

Enroll in Course